ThromboGenics licenses AMP-Rx protein design technology from Eleven

Commenting on the agreement, ThromboGenics CEO Dr Patrik De Haes said, "This is an important step forward as we continue to build our ophthalmology franchise following the recent introduction of JETREA for the treatment of symptomatic vitreomacular adhesion (VMA)/ vitreomacular traction (VMT) in the US and Europe."

The technology will be leveraged in the development of a new protein therapeutic against a biologic target identified by ThromboGenics and is concerned with a range of diabetic eye diseases.

As per the terms of the deal, ThromboGenics holds exclusive license to all future developments and commercialization of the novel protein and will make an undisclosed upfront payment to Eleven, which is also eligible for development, regulatory and sales milestone payments in addition to sales-based royalties.

Eleven Biotherapeutics president and CEO Abbie Celniker said, "Eleven’s novel approach to designing protein therapeutics for ocular diseases, which has been demonstrated with EBI-005, our lead product candidate in Phase 1b clinical development for dry eye disease, will be applied to discover and optimize novel modulators of this evolving pathway which is central to ophthalmic disease."